<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v3.0 20080202//EN" "archivearticle3.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><front><journal-meta><journal-id journal-id-type="nlm-ta">PLoS One</journal-id><journal-id journal-id-type="publisher-id">plos</journal-id><journal-id journal-id-type="pmc">plosone</journal-id><journal-title-group><journal-title>PLoS ONE</journal-title></journal-title-group><issn pub-type="epub">1932-6203</issn><publisher><publisher-name>Public Library of Science</publisher-name><publisher-loc>San Francisco, USA</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">09-PONE-RA-09708R1</article-id><article-id pub-id-type="doi">10.1371/journal.pone.0006567</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="Discipline"><subject>Oncology</subject><subject>Biochemistry/Biomacromolecule-Ligand Interactions</subject><subject>Biochemistry/Cell Signaling and Trafficking Structures</subject><subject>Biophysics/Biomacromolecule-Ligand Interactions</subject><subject>Biophysics/Cell Signaling and Trafficking Structures</subject></subj-group></article-categories><title-group><article-title>The TCL1A Oncoprotein Interacts Directly with the NF-&#x003ba;B Inhibitor I&#x003ba;B</article-title><alt-title alt-title-type="running-head">TCL1A Interacts with I&#x003ba;B</alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Ropars</surname><given-names>Virginie</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff3"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Despouy</surname><given-names>Gilles</given-names></name><xref ref-type="aff" rid="aff4"><sup>4</sup></xref><xref ref-type="aff" rid="aff5"><sup>5</sup></xref><xref ref-type="author-notes" rid="fn1"><sup>&#x000a4;</sup></xref></contrib><contrib contrib-type="author"><name><surname>Stern</surname><given-names>Marc-Henri</given-names></name><xref ref-type="aff" rid="aff4"><sup>4</sup></xref><xref ref-type="aff" rid="aff5"><sup>5</sup></xref></contrib><contrib contrib-type="author"><name><surname>Benichou</surname><given-names>Serge</given-names></name><xref ref-type="aff" rid="aff6"><sup>6</sup></xref><xref ref-type="aff" rid="aff7"><sup>7</sup></xref></contrib><contrib contrib-type="author"><name><surname>Roumestand</surname><given-names>Christian</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff3"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Arold</surname><given-names>Stefan T.</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="corresp" rid="cor1"><sup>&#x0002a;</sup></xref></contrib></contrib-group><aff id="aff1"><label>1</label><addr-line>CNRS, UMR5048, Centre de Biochimie Structurale, Montpellier, France</addr-line></aff><aff id="aff2"><label>2</label><addr-line>INSERM, U554, Montpellier, France</addr-line></aff><aff id="aff3"><label>3</label><addr-line>Universit&#x000e9;s Montpellier 1 &#x00026; 2, Montpellier, France</addr-line></aff><aff id="aff4"><label>4</label><addr-line>Institut Curie, Centre de Recherche, Paris, France</addr-line></aff><aff id="aff5"><label>5</label><addr-line>INSERM U830, Paris, France</addr-line></aff><aff id="aff6"><label>6</label><addr-line>Institut Cochin, Universit&#x000e9; Paris Descartes, CNRS, UMR 8104, Inserm U567, Paris, France</addr-line></aff><aff id="aff7"><label>7</label><addr-line>Inserm U567, Paris, France</addr-line></aff><contrib-group><contrib contrib-type="editor"><name><surname>Kobe</surname><given-names>Bostjan</given-names></name><role>Editor</role><xref ref-type="aff" rid="edit1"/></contrib></contrib-group><aff id="edit1">University of Queensland, Australia</aff><author-notes><corresp id="cor1">&#x0002a; E-mail: <email>Stefan.Arold@cbs.cnrs.fr</email></corresp><fn fn-type="con"><p>Conceived and designed the experiments: MHS CR STA. Performed the experiments: VR GD MHS SB. Analyzed the data: VR GD MHS CR STA. Contributed reagents/materials/analysis tools: GD MHS SB. Wrote the paper: STA.</p></fn><fn id="fn1" fn-type="current-aff"><label>&#x000a4;</label><p>Current address: Universit&#x000e9; de Franche-Comt&#x000e9;, IFR 133, UFR-ST, Equipe E3922, Besan&#x000e7;on, France</p></fn></author-notes><pub-date pub-type="collection"><year>2009</year></pub-date><pub-date pub-type="epub"><day>10</day><month>8</month><year>2009</year></pub-date><volume>4</volume><issue>8</issue><elocation-id>e6567</elocation-id><history><date date-type="received"><day>11</day><month>4</month><year>2009</year></date><date date-type="accepted"><day>1</day><month>7</month><year>2009</year></date></history><permissions><copyright-statement>Ropars et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</copyright-statement></permissions><abstract><p>The T cell leukaemia/lymphoma 1A (TCL1A) oncoprotein plays key roles in several B and T cell malignancies. Lacking enzymatic activity, TCL1A's transforming action was linked to its capacity to co-activate the protein kinase AKT <italic>via</italic> binding to its pleckstrin homology (PH) domain. However, perturbation of AKT signalling alone was recently shown insufficient to explain TCL1A oncogenesis, suggesting that TCL1A has additional cellular partners. Searching for such additional targets, we found that TCL1A binds specifically and directly to the ankyrin domain of I&#x003ba;B, the inhibitor of the NF-&#x003ba;B transcription factors. Through binding assays and a structural analysis by small angle X-ray scattering, we show that TCL1A and I&#x003ba;B interact in yeast-two-hybrid systems, when transiently overexpressed in 293 cells, and as recombinant proteins <italic>in vitro</italic>. We further establish that the association between TCL1A and I&#x003ba;B is compatible with AKT binding to TCL1A, but incompatible with I&#x003ba;B binding to NF-&#x003ba;B. By interfering with the inhibition of NF-&#x003ba;B by I&#x003ba;B, TCL1A may increase the concentration of free NF-&#x003ba;B molecules sufficiently to trigger expression of anti-apoptotic genes. Thus our data suggest an additional route by which TCL1A might cause cancer.</p></abstract><counts><page-count count="7"/></counts></article-meta></front><body><sec id="s1"><title>Introduction</title><p>TCL1-family proteins (TCL1A, TCL1B and MTCP1 in humans) are 13&#x02013;15 kDa non-enzymatic interaction modules. Their restricted physiological expression and apparent lack of auto-regulatory mechanisms suggest that they are mainly regulated by tightly controlled gene expression levels. Normal time- and tissue-restricted expression of <italic>TCL1</italic> genes is important for efficient fertility, and the development of T and B cell lineages. Deregulation of <italic>TCL1</italic> expression can cause the transformation of mature human T and B lymphocytes, and is associated with a variety of human diseases, including T-cell prolymphocytic leukaemia, B-cell chronic leukaemia (B-CLL), B-cell lymphoma and germ-cell tumours &#x0005b;reviewed in <xref ref-type="bibr" rid="pone.0006567-Teitell1">&#x0005b;1&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0006567-Noguchi1">&#x0005b;2&#x0005d;</xref>&#x0005d;.</p><p>TCL1A is a co-activator of AKT, a serine/threonine protein kinase that regulates many cellular processes, including proliferation and survival <xref ref-type="bibr" rid="pone.0006567-Laine1">&#x0005b;3&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0006567-Pekarsky1">&#x0005b;4&#x0005d;</xref>. TCL1A forms homodimers, and each protomer binds one pleckstrin homology (PH) domain of AKT <xref ref-type="bibr" rid="pone.0006567-Auguin1">&#x0005b;5&#x0005d;</xref>. Co-activation may thus result from stabilising AKT in an open (active) conformation, from promoting AKT auto-phosphorylation in <italic>trans</italic>, and/or from reinforcing AKT attachment to the membrane, where its effectors are located <xref ref-type="bibr" rid="pone.0006567-Teitell1">&#x0005b;1&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0006567-Noguchi1">&#x0005b;2&#x0005d;</xref>. Activated AKT can promote cell survival by phosphorylating downstream targets such as BAD <xref ref-type="bibr" rid="pone.0006567-Manning1">&#x0005b;6&#x0005d;</xref>. AKT can also activate the NF-&#x003ba;B transcription factor, possibly by phosphorylating the I&#x003ba;B kinase (IKK)<xref ref-type="bibr" rid="pone.0006567-Ozes1">&#x0005b;7&#x0005d;</xref>. Phosphorylated IKK phosphorylates I&#x003ba;B, leading to dissociation of the I&#x003ba;B:NF-&#x003ba;B complex. Liberated NF-&#x003ba;B subsequently translocates to the nucleus to activate survival-inducing genes <xref ref-type="bibr" rid="pone.0006567-Hayden1">&#x0005b;8&#x0005d;</xref>.</p><p>However, the effects of TCL1A on AKT are insufficient to fully explain TCL1A oncogenesis. For example, AKT phosphorylation or inactivation kinetics do not consistently relate to TCL1A expression in both transgenic mice and patient&#x02013;derived neoplasia, and AKT activation alone does not necessarily cause tumours in B cells <xref ref-type="bibr" rid="pone.0006567-Teitell1">&#x0005b;1&#x0005d;</xref>. This suggests that additional effects, and effectors, of TCL1A exist. Recently, it was reported that the NF-&#x003ba;B pathway is important for B-CLL in transgenic mouse models (reviewed in <xref ref-type="bibr" rid="pone.0006567-Pekarsky2">&#x0005b;9&#x0005d;</xref>), and that TCL1A activates NF-&#x003ba;B through an AKT-independent route <xref ref-type="bibr" rid="pone.0006567-Pekarsky3">&#x0005b;10&#x0005d;</xref>. Corroborating an AKT-independent targeting of NF-&#x003ba;B by TCL1A, we here report that TCL1A binds directly to the NF-&#x003ba;B inhibitor I&#x003ba;B.</p></sec><sec id="s2"><title>Results</title><p>In a search for additional partners of TCL1A, we identified I&#x003ba;B&#x003b1; through yeast two-hybrid screening. The prey consisted of residues 73&#x02013;317 of I&#x003ba;B&#x003b1;, and included the six ankyrin repeats that bind NF-&#x003ba;B <xref ref-type="bibr" rid="pone.0006567-Huxford1">&#x0005b;11&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0006567-Jacobs1">&#x0005b;12&#x0005d;</xref> (<xref ref-type="fig" rid="pone-0006567-g001">Figure 1a</xref>). After over-expression of I&#x003ba;B&#x003b1; and FLAG-TCL1A in 293 cells, I&#x003ba;B&#x003b1; coimmunoprecipitated with TCL1A, demonstrating that these proteins can interact in a cellular context (<xref ref-type="fig" rid="pone-0006567-g001">Figure 1b</xref>). GST-TCL1A interacted significantly more strongly with I&#x003ba;B&#x003b1; than did GST-MTCP1 (<xref ref-type="fig" rid="pone-0006567-g001">Figure 1c</xref>). Conversely, two-hybrid, gel shift, and fluorescence anisotropy assays failed to detect an interaction between MTCP1 and I&#x003ba;B&#x003b1; (data not shown). <italic>In vitro</italic>, GST-TCL1A bound the AKT&#x003b2; PH domain (AKT_PH; residues 1&#x02013;118), and an all-cysteine-to-serine (7CS) mutant of the I&#x003ba;B&#x003b1; ankyrin domain (I&#x003ba;B_ank, residues 67&#x02013;302; the C-&#x0003e;S substitutions were made to avoid non-specific aggregation through cys-cys di-sulphide bridges), but not the ankyrin domain of the <italic>Drosophila</italic> signalling protein Notch (<xref ref-type="supplementary-material" rid="pone.0006567.s001">Figure S1a</xref>).</p><fig id="pone-0006567-g001" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0006567.g001</object-id><label>Figure 1</label><caption><title>Cell-based binding assays.</title><p>(a) Schematic representation of I&#x003ba;B&#x003b1;. (b) Co-immunoprecipitation assay. Input 2&#x00025;: 2&#x00025; of the whole extract used for the immunoprecipitation. IP control: Immunoprecipitation with irrelevant antibody (anti-HA). (c,d) &#x0005b;<sup>35</sup>S&#x0005d;-labeled I&#x003ba;B&#x003b1; or I&#x003ba;B&#x003b1;<sub>1&#x02013;253</sub> produced by <italic>in vitro</italic> transcription/translation in rabbit reticulocytes lysate, were incubated with GST, GST-MTCP1 and GST-TCL1A immobilized on glutathione-sepharose beads. Bound proteins were resolved by 12&#x00025; SDS-PAGE and detected by autoradiography.</p></caption><graphic xlink:href="pone.0006567.g001"/></fig><p>Native SDS PAGE gel shift assays showed that AKT_PH, I&#x003ba;B_ank and I&#x003ba;B_ank<sup>7CS</sup> retarded migration of TCL1A (<xref ref-type="fig" rid="pone-0006567-g002">Figure 2</xref>, <xref ref-type="supplementary-material" rid="pone.0006567.s001">Figure S1b,c</xref>). Using isothermal titration calorimetry (ITC), TCL1A displayed a dissociation constant (K<sub>D</sub>) of 7.5&#x000b1;1.0 &#x000b5;M for AKT_PH, in agreement with previous NMR measurements <xref ref-type="bibr" rid="pone.0006567-Auguin1">&#x0005b;5&#x0005d;</xref> (<xref ref-type="table" rid="pone-0006567-t001">Table 1</xref>, and <xref ref-type="supplementary-material" rid="pone.0006567.s002">Figure S2a</xref>). TCL1A bound I&#x003ba;B_ank<sup>7CS</sup> with a K<sub>D</sub> of 0.71&#x000b1;0.07 &#x000b5;M (<xref ref-type="fig" rid="pone-0006567-g003">Figure 3</xref>). Placing the 1&#x02236;1 TCL1A&#x02236;I&#x003ba;B_ank<sup>7CS</sup> complex in the ITC cell slightly increased the affinity of injected AKT_PH (K<sub>D</sub>&#x0200a;&#x0003d;&#x0200a;5.1&#x000b1;0.5 &#x000b5;M), as compared to titrations with only TCL1A in the cell. This showed that binding of I&#x003ba;B_ank and AKT_PH to TCL1A are compatible and slightly cooperative events (<xref ref-type="supplementary-material" rid="pone.0006567.s002">Figure S2b</xref>). Conversely, when the cell was filled with I&#x003ba;B_ank<sup>7CS</sup> bound to the NF-&#x003ba;B family member RELA, injection of TCL1A yielded curves with a K<sub>D</sub>&#x0226b;50 &#x000b5;M, inferring that binding of TCL1A and RELA to I&#x003ba;B_ank are incompatible events (data not shown). Competition between TCL1A and RELA for I&#x003ba;B_ank was confirmed by gel shift assays (<xref ref-type="fig" rid="pone-0006567-g002">Figure 2c</xref>).</p><fig id="pone-0006567-g002" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0006567.g002</object-id><label>Figure 2</label><caption><title>Native gel shift assays.</title><p>(a&#x02013;c): Bands corresponding to the complexes formed are indicated on the right of each figure. (b,c): The three lanes on the right correspond to increasing concentrations of I&#x003ba;B_ank<sup>7CS</sup> (b) or RELA (c).</p></caption><graphic xlink:href="pone.0006567.g002"/></fig><fig id="pone-0006567-g003" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0006567.g003</object-id><label>Figure 3</label><caption><title>ITC analysis.</title><p>TCL1A at 470 &#x000b5;M was injected into the measurement cell containing I&#x003ba;B_ank<sup>7CS</sup> at 45 &#x000b5;M. The titration was carried out at 20&#x000b0;C. The upper panel shows the binding isotherm, the lower panels shows the integrated heats.</p></caption><graphic xlink:href="pone.0006567.g003"/></fig><table-wrap id="pone-0006567-t001" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0006567.t001</object-id><label>Table 1</label><caption><title>Summary of ITC data.</title></caption><alternatives><graphic id="pone-0006567-t001-1" xlink:href="pone.0006567.t001"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1">Syringe/Cell</td><td align="left" rowspan="1" colspan="1">K<sub>D</sub> (&#x000b5;M)</td><td align="left" rowspan="1" colspan="1">N</td><td align="left" rowspan="1" colspan="1">&#x00394;H (kJ/mol)</td><td align="left" rowspan="1" colspan="1">&#x003a4;&#x00394;S (kJ/mol)</td><td align="left" rowspan="1" colspan="1">&#x00394;G (kJ/mol)</td></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">AKT_PH/TCL1A</td><td align="left" rowspan="1" colspan="1">7.5&#x000b1;1.0</td><td align="left" rowspan="1" colspan="1">0.7&#x000b1;0.3<xref ref-type="table-fn" rid="nt102">a</xref></td><td align="left" rowspan="1" colspan="1">&#x02212;60.9&#x000b1;2.5</td><td align="left" rowspan="1" colspan="1">&#x02212;29.9</td><td align="left" rowspan="1" colspan="1">&#x02212;31.0</td></tr><tr><td align="left" rowspan="1" colspan="1">AKT_PH/TCL1A:I&#x003ba;B</td><td align="left" rowspan="1" colspan="1">5.1&#x000b1;0.5</td><td align="left" rowspan="1" colspan="1">0.7&#x000b1;0.3<xref ref-type="table-fn" rid="nt102">a</xref></td><td align="left" rowspan="1" colspan="1">&#x02212;39.0&#x000b1;1.2</td><td align="left" rowspan="1" colspan="1">&#x02212;9.4</td><td align="left" rowspan="1" colspan="1">&#x02212;29.7</td></tr><tr><td align="left" rowspan="1" colspan="1">TCL1A/I&#x003ba;B</td><td align="left" rowspan="1" colspan="1">0.71&#x000b1;0.07</td><td align="left" rowspan="1" colspan="1">0.9&#x000b1;0.1</td><td align="left" rowspan="1" colspan="1">&#x02212;53.2&#x000b1;0.5</td><td align="left" rowspan="1" colspan="1">&#x02212;17.9</td><td align="left" rowspan="1" colspan="1">&#x02212;35.3</td></tr><tr><td align="left" rowspan="1" colspan="1">TCL1A/I&#x003ba;B:RELA</td><td align="left" rowspan="1" colspan="1">&#x0226b;50</td><td align="left" rowspan="1" colspan="1">n.d.</td><td align="left" rowspan="1" colspan="1">n.d.</td><td align="left" rowspan="1" colspan="1">n.d.</td><td align="left" rowspan="1" colspan="1">n.d.</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="nt101"><p>n.d.: not determined.</p></fn><fn id="nt102"><label>a</label><p>A 1&#x02236;1 stoichiometry can be deduced from our previous analyses <xref ref-type="bibr" rid="pone.0006567-Auguin1">&#x0005b;5&#x0005d;</xref>.</p></fn></table-wrap-foot></table-wrap><p>In the absence of successful TCL1A&#x02236;I&#x003ba;B crystallisation trials, we used small angle X-ray scattering (SAXS) to obtain structural information on the complex. Guinier analysis and data processing by GNOM <xref ref-type="bibr" rid="pone.0006567-Koch1">&#x0005b;13&#x0005d;</xref> established a radius of gyration of 4.5&#x000b1;0.2 nm and a maximum diameter of 15.0&#x000b1;0.5 nm. The P(r) distance distribution obtained for TCL1A&#x02236;I&#x003ba;B_ank<sup>7CS</sup> displayed a triangular shape indicative for an elongated particle (<xref ref-type="supplementary-material" rid="pone.0006567.s003">Figure S3a</xref>). Initial <italic>ab initio</italic> shape calculations with DAMMIN <xref ref-type="bibr" rid="pone.0006567-Koch1">&#x0005b;13&#x0005d;</xref> without symmetry constraints yielded elongated particles with a volume of 12.7&#x000d7;10<sup>4</sup> &#x000c5;<sup>3</sup>, comparable to the one of a 2&#x000d7;(TCL1A&#x02236;I&#x003ba;B_ank) complex (11.0&#x000d7;10<sup>4</sup> &#x000c5;<sup>3</sup>, calculated without hydration shell). The Z-shape of these reconstructions was suggestive of a P2 symmetry (data not shown). Because TCL1A forms stable dimers in solution <xref ref-type="bibr" rid="pone.0006567-Auguin1">&#x0005b;5&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0006567-Hoh1">&#x0005b;14&#x0005d;</xref>, we subsequently used P2 symmetry for iterative <italic>ab initio</italic> shape reconstructions with the program GASBOR <xref ref-type="bibr" rid="pone.0006567-Svergun1">&#x0005b;15&#x0005d;</xref>. The best scored <italic>ab initio</italic> structure out of 40 individual GASBOR runs fitted data between q&#x0200a;&#x0003d;&#x0200a;0.02 and 0.45 &#x000c5;<sup>&#x02212;1</sup> with a &#x003c7; value of 1.02 (CRYSOL <xref ref-type="bibr" rid="pone.0006567-Svergun2">&#x0005b;16&#x0005d;</xref>; <xref ref-type="supplementary-material" rid="pone.0006567.s003">Figure S3b</xref>). This SAXS envelope is composed of a trapeze-shaped central domain, and two laterally attached rod-like domains (<xref ref-type="fig" rid="pone-0006567-g004">Figure 4b</xref>). The dimensions of the central and rod-like domains correspond to those of the crystal structures of the TCL1A dimer <xref ref-type="bibr" rid="pone.0006567-Hoh1">&#x0005b;14&#x0005d;</xref> and I&#x003ba;B_ank monomer <xref ref-type="bibr" rid="pone.0006567-Huxford1">&#x0005b;11&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0006567-Jacobs1">&#x0005b;12&#x0005d;</xref>, respectively. The <italic>ab inito</italic> shape suggested that TCL1A binds either to the N- or C-terminal ankyrin repeats of I&#x003ba;B_ank. Since the C-terminal sixth ankyrin repeat of I&#x003ba;B&#x003b1; was dispensable for binding (<xref ref-type="fig" rid="pone-0006567-g001">Figure 1d</xref>), our analysis supports that TCL1A principally contacts the first N-terminal ankyrin repeats of I&#x003ba;B&#x003b1;.</p><fig id="pone-0006567-g004" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0006567.g004</object-id><label>Figure 4</label><caption><title>SAXS analysis.</title><p>(a) SAXS curve (red) calculated from the molecular model depicted in b, fitted to SAXS data (black). (b) Best-scored SASREF model (surface representation). The TCL1A dimer (taken from PDB entry 1JSG <xref ref-type="bibr" rid="pone.0006567-Hoh1">&#x0005b;14&#x0005d;</xref>) is shown in two shades of violet. The AKT_PH binding sites of TCL1A (determined previously by NMR mapping <xref ref-type="bibr" rid="pone.0006567-Auguin1">&#x0005b;5&#x0005d;</xref>) are coloured yellow. I&#x003ba;B_ank (taken from PDB entry 1NFI <xref ref-type="bibr" rid="pone.0006567-Jacobs1">&#x0005b;12&#x0005d;</xref>) is shown in blue. The disordered 20 C-terminal tail residues of I&#x003ba;B_ank (dark blue), and 7 N-terminal residues of TCL1A (light pink) were not included in the crystal structures. These fragments were modelled placed by SASREF as described in the <xref ref-type="sec" rid="s4">Materials and Methods</xref> section. Because the dimensions of the <italic>ab initio</italic> GASBOR envelope (pink spheres) suggested that the 20 residues C-terminal tail residues of I&#x003ba;B_ank are pinned back onto the ankyrin repeats, this constraint was used in SASREF runs. We speculate that hydrophobic tail residues (such as F295 and F298) may cover hydrophobic surfaces on the ankyrin repeats that are also used by NF-&#x003ba;B. (c) The SASREF model is superimposed onto the &#x02018;filtered&#x02019; average envelope (grey spheres) which was calculated by DAMAVER (file &#x02018;damfilt&#x02019;) from the 20&#x00025; top SASREF solutions. The superimposition in DAMAVER was achieved allowing use of enantiomers. At the low resolution used, models where the C-terminus of the left I&#x003ba;B_ank molecule points down, and the right one up (using the orientation of the lower panel) resemble enantiomers of the model displayed. Since SAXS is unable to distinguish between enantiomers, models with both I&#x003ba;B_ank orientations were found among the top 20&#x00025; best scored SASREF models; the orientation of the model displayed is used by 70&#x00025; of the top 20&#x00025; solutions, and may therefore be more likely.</p></caption><graphic xlink:href="pone.0006567.g004"/></fig><p>We next used the crystal structures of TCL1A and I&#x003ba;B_ank to perform SAXS-guided rigid body docking with the program SASREF <xref ref-type="bibr" rid="pone.0006567-Koch1">&#x0005b;13&#x0005d;</xref>. The information that TCL1A binds to the N- and not the C-terminal of I&#x003ba;B_ank was used as a constraint. The best-scored 20 structures out of 100 individual Monte-Carlo-based simulated annealing calculations were averaged using DAMAVER <xref ref-type="bibr" rid="pone.0006567-Volkov1">&#x0005b;17&#x0005d;</xref>. The representative structure determined by DAMAVER, which was also the one with the best fit of all SASREF runs (&#x003c7; fit to data between q&#x0200a;&#x0003d;&#x0200a;0.02 and 0.40 &#x000c5;<sup>&#x02212;1</sup> was 1.02; <xref ref-type="fig" rid="pone-0006567-g004">Figure 4a</xref>), corresponded well to the <italic>ab initio</italic> GASBOR envelope (<xref ref-type="fig" rid="pone-0006567-g004">Figure 4b</xref>). Rg and Dm values for this structure (42.3 &#x000c5; and 144.2 &#x000c5;, respectively, calculated without hydration shell) were in good agreement with values obtained from GNOM and Guinier analysis for the hydrated particle (4.5&#x000b1;0.2 nm and 15.0&#x000b1;0.5 nm).</p><p>Our structural analysis suggests that TCL1A uses a binding site roughly opposite to its dimerisation site to interact with the first one or two ankyrin repeats of I&#x003ba;B_ank. Thus TCL1A may compete with helices &#x003b1;A and &#x003b1;B of RELA <xref ref-type="bibr" rid="pone.0006567-Huxford1">&#x0005b;11&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0006567-Jacobs1">&#x0005b;12&#x0005d;</xref>. The I&#x003ba;B_ank binding site is close to, but not overlapping with, the AKT_PH binding surface on TCL1A <xref ref-type="bibr" rid="pone.0006567-Auguin1">&#x0005b;5&#x0005d;</xref>, corroborating that TCL1A can bind I&#x003ba;B and AKT simultaneously.</p></sec><sec id="s3"><title>Discussion</title><p>Several lines of evidence suggest an AKT-independent action of TCL1A on NF-&#x003ba;B pathways <xref ref-type="bibr" rid="pone.0006567-Pekarsky2">&#x0005b;9&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0006567-Pekarsky3">&#x0005b;10&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0006567-Despouy1">&#x0005b;18&#x0005d;</xref>. We here sharpened this picture by showing that TCL1A and the NF-&#x003ba;B inhibitor I&#x003ba;B associate <italic>in vitro</italic>, in yeast-two-hybrid systems, and when transiently overexpressed in 293 cells. We also showed <italic>in vitro</italic> that TCL1A competed with NF-&#x003ba;B for binding to I&#x003ba;B, suggesting that TCL1A interferes with the inhibitory interaction between I&#x003ba;B and NF-&#x003ba;B. Since TCL1A binds to the same first two ankyrin repeats of I&#x003ba;B which also interact with helices &#x003b1;A and &#x003b1;B of RELA <xref ref-type="bibr" rid="pone.0006567-Huxford1">&#x0005b;11&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0006567-Jacobs1">&#x0005b;12&#x0005d;</xref>, it is likely that TLC1A and RELA use overlapping binding sites on I&#x003ba;B. However, we can not exclude that I&#x003ba;B binding to one partner causes conformational changes (such as a slight change in the curvature of the ankyrin repeats) that affect allosterically the (distant) binding site of the other partner.</p><p>On a cellular level, the effect expected to arise from the competition of TCL1A and NF-&#x003ba;B for I&#x003ba;B would be an AKT-independent NF-&#x003ba;B-activation by TCL1A. This was indeed recently observed by Pekarsky et al. <xref ref-type="bibr" rid="pone.0006567-Pekarsky3">&#x0005b;10&#x0005d;</xref>. These authors reported that this effect involves the association between TCL1A and p300. The molecular details of the association between TCL1A and p300 remain elusive. Since both proteins are multivalent adaptor proteins, sequential or concomitant interactions of TCL1A with I&#x003ba;B are not excluded, and may be necessary for activation of NF-&#x003ba;B.</p><p>The description of several AKT-independent TCL1A targets suggests that TCL1A affects a number of alternative and interconnected signalling pathways (<xref ref-type="bibr" rid="pone.0006567-Pekarsky3">&#x0005b;10&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0006567-Despouy1">&#x0005b;18&#x0005d;</xref>, and this report). Indeed, depending on the cell type and experimental conditions, both NF-&#x003ba;B activation and inhibition by TCL1A were reported, as well as alternative, NF-&#x003ba;B independent routes (inhibition of PKC&#x003b8; and ERK activation, or of AP-1 transcriptional activity) <xref ref-type="bibr" rid="pone.0006567-Pekarsky3">&#x0005b;10&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0006567-Despouy1">&#x0005b;18&#x0005d;</xref>. Thus, TCL1A increasingly appears as a polyvalent adaptor protein, whose cellular action is dramatically affected by its sub-cellular concentration and the availability of potential targets.</p><p>The affinity we measured between I&#x003ba;B and TCL1A was about 1,000 fold weaker than the one previously reported between I&#x003ba;B and NF-&#x003ba;B <xref ref-type="bibr" rid="pone.0006567-Bergqvist1">&#x0005b;19&#x0005d;</xref>. However, since only a minor fraction of cytoplasmic NF-&#x003ba;B is enough to trigger transcriptional activation <xref ref-type="bibr" rid="pone.0006567-Tergaonkar1">&#x0005b;20&#x0005d;</xref>, even weak competition by TCL1A is expected to alter gene expression through NF-&#x003ba;B. Yet this effect will be caused by only a negligible fraction of cellular I&#x003ba;B and NF-&#x003ba;B, which may explain why we were unable to detect significant amounts of TCL1A-I&#x003ba;B complexes in absence of transient overexpression, as searched for in 697 and Sup-T11 TCL1-positive leukaemic cell lines (data not shown). In addition, a biologically significant effect on the I&#x003ba;B&#x02236;NF-&#x003ba;B complex is likely to require TCL1A over-expression following chromosomal translocation, and/or additional factors, such as AKT, p300, or factors associated with a particular cell activation level. Importantly, TCL1A also needs co-stimulatory signals to induce AKT activation (possibly the association of AKT_PH with PIP<sub>3</sub><xref ref-type="bibr" rid="pone.0006567-Noguchi1">&#x0005b;2&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0006567-Laine1">&#x0005b;3&#x0005d;</xref>), and the requirement of co-activators may constitute an additional control mechanism for TCL1A.</p><p>Given that TCL1A binds I&#x003ba;B and AKT_PH simultaneously <italic>in vitro</italic>, TCL1A may act on I&#x003ba;B and AKT synergistically or independently. In its physiological location, the 5&#x02032; promoter region of the <italic>TCL1A</italic> gene contains, among others, an NF-&#x003ba;B-responsive <italic>cis</italic>-regulatory element <xref ref-type="bibr" rid="pone.0006567-Ozes1">&#x0005b;7&#x0005d;</xref>. Through the action of TCL1A on I&#x003ba;B or AKT, this element may produce a positive feed-back loop to enhance TCL1A expression. Thus, the association between TCL1A and I&#x003ba;B could contribute to transcriptional regulation of TCL1A.</p><p>Future research will be necessary to clarify the <italic>in vivo</italic> significance and role of the TCL1A-I&#x003ba;B interaction for oncogenesis. However, given that TCL1A appears to be a polyvalent adaptor protein with multiple cellular partners, it will be far from trivial to design a cell-based assay that allows observing a molecular effect based solely on this TCL1A-I&#x003ba;B interaction. Moreover, because only an extremely low fraction of cellular I&#x003ba;B&#x02236;NF-&#x003ba;B complexes is predicted to be affected by TCL1A, it will be difficult to use intracellular detection methods based on endogenous protein (for example co-localisation studies by immunofluorescence, or co-immunoprecipation experiments). The identification of potential binding surfaces by our structural characterisation of the TCL1A-I&#x003ba;B interaction may however help resolving these issues.</p></sec><sec sec-type="materials|methods" id="s4"><title>Materials and Methods</title><sec id="s4a"><title>Yeast two-hybrid screening of TCL1A</title><p>The yeast two hybrid screening was performed as previously described <xref ref-type="bibr" rid="pone.0006567-Bouhamdan1">&#x0005b;21&#x0005d;</xref>. Briefly the yeast reporter strain HF7c was transformed by the lithium acetate method with the bait plasmid pGBT10-TCL1A. After selection and transformation with a peripheral blood mononuclear cell cDNA library cloned into the pGAD plasmid, approximately 2.10<sup>6</sup> clones were screened for HIS&#x0002b;&#x003b2;GAL&#x0002b; colonies. Out of the 30 HIS&#x0002b;&#x003b2;GAL&#x0002b; colonies sequenced, 28 corresponded to the 735 nucleotides at the 3&#x02032; end of I&#x003ba;B&#x003b1; transcripts.</p></sec><sec id="s4b"><title>Binding analysis through retention by glutathione-sepharose-bound GST-TCL1A</title><p>Recombinant GST-TCL1A and GST-MTCP1 were expressed in <italic>E. coli</italic>, bound to glutathione-sepharose beads (Pharmacia), and placed into Handee Centrifuge Columns. Unbound material was removed by washing the beads four times with 100 column volumes of TN300 (10 mM Tris, pH 7.4 and 300 mM NaCl). Beads were incubated for 1 h at 4&#x000b0;C with 3 mg of AKT_PH, I&#x003ba;B_ank<sup>7CS</sup>, or the Drosophila Notch ankyrin-repeat protein and washed with 15 column volumes with TN300. The bound proteins were visualized using SDS PAGE gel under denaturing conditions. Alternatively, GST proteins bound to the beads were incubated with rabbit reticulocyte lysates containing &#x0005b;<sup>35</sup>S&#x0005d;-labeled translated I&#x003ba;B&#x003b1; or I&#x003ba;B&#x003b1;<sub>1&#x02013;253</sub> (T7 Quick Coupled Transcription/Translation System, Promega Madison, WI). Equal loading of the GST fusion proteins was confirmed by Coomassie staining. Input corresponds to 5&#x00025; of the total protein content used for the pull-down. Bound I&#x003ba;B&#x003b1; and I&#x003ba;B&#x003b1;<sub>1&#x02013;253</sub> were recovered in SDS loading buffer, resolved by 12&#x00025; SDS-PAGE and analyzed by autoradiography of dried gels.</p></sec><sec id="s4c"><title>Co-immunoprecipitation assay</title><p>293 cells were transiently transfected with pCMV2-FLAG-TCL1A (Sigma-Aldrich, Saint Quentin Fallavier, France) and pCMV-I&#x003ba;B&#x003b1;, using the calcium phosphate precipitation technique as described <xref ref-type="bibr" rid="pone.0006567-Despouy2">&#x0005b;22&#x0005d;</xref>. Cell extracts were incubated with a mouse anti-Flag antibody (Sigma-Aldrich) for 16 h and then with protein G-Sepharose (Amersham Pharmacia Biotech) for an additional hour. The immunocomplexes were recovered by centrifugation, washed and resolved by SDS-PAGE. The immunoprecipitated proteins were revealed by immunoblotting and chemiluminescence.</p></sec><sec id="s4d"><title>Western Blot analysis</title><p>For Western Blot analysis, the native gels were applied to a PolyScreen PVDF transfer membrane (NEN Life Science Products). Membranes were treated as suggested by the manufacturer, and incubated with mouse anti-I&#x003ba;B&#x003b1; antibody (1 h at room temperature), followed by membrane washing in the Tris-buffered saline. Membranes were then incubated with anti-mouse IgG linked to horseradish (30 min at room temperature). Membranes were washed following the manufacturer's directions, and ECL detection reagents were added. Kodak biomax light film was exposed to membranes for &#x0223c;25 s. The positions of the complexes formed are indicated.</p></sec><sec id="s4e"><title>Recombinant protein production</title><p>The pET11a expression plasmid for human I&#x003ba;B<sub>67&#x02013;302</sub> (I&#x003ba;B_ank) was provided by G. Ghosh. The NF-&#x003ba;B family member RELA/p65, cloned into pGEX2T, was provided by M. Benkirane. I&#x003ba;B and RELA were expressed and purified as described <xref ref-type="bibr" rid="pone.0006567-Huxford2">&#x0005b;23&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0006567-Kiernan1">&#x0005b;24&#x0005d;</xref>. Human TCL1A and human AKT&#x003b2; PH<sub>1&#x02013;118</sub> (AKT_PH) were produced as published <xref ref-type="bibr" rid="pone.0006567-Hoh1">&#x0005b;14&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0006567-Auguin2">&#x0005b;25&#x0005d;</xref>. The Cys-&#x0003e;Ser mutant I&#x003ba;B<sub>67&#x02013;302</sub><sup>7CS</sup> (I&#x003ba;B_ank<sup>7CS</sup>) was obtained using Stratagene's QuikChange multi-site directed mutagenesis Kit. The purified recombinant ankyrin domain of the <italic>Drosophila</italic> signalling protein Notch was provided by J.-B. Rouget.</p></sec><sec id="s4f"><title>PAGE gel shift assays</title><p>Undenatured (native) polyacrylamide gel electrophoresis (PAGE) was performed with purified recombinant proteins. Running gels contained 15&#x00025; (w/v) polyacrylamide and 0.125 M Tris (pH 6.8). Stacking gels contained 5&#x00025; (w/v) polyacrylamide and 0.375 M Tris (pH 8.8). For additional Western blot analysis, the native gels were applied to a PolyScreen PVDF transfer membrane (NEN Life Science Products). Membranes were treated as suggested by the manufacturer, and incubated with mouse anti-I&#x003ba;B&#x003b1; antibody (1 h at room temperature), followed by membrane washing in the Tris-buffered saline. Membranes were then incubated with anti-mouse IgG linked to horseradish (30 min at room temperature). Membranes were washed following the manufacturer's directions, and ECL detection reagents were added. Kodak biomax light film was exposed to membranes for &#x0223c;25 s.</p></sec><sec id="s4g"><title>Isothermal titration calorimetry (ITC)</title><p>Purified TCL1A, I&#x003ba;B_ank<sup>7CS</sup>, RELA and AKT_PH were extensively dialysed in degassed ITC buffer. The TCL1A - I&#x003ba;B_ank<sup>7CS</sup> titrations were carried out in a buffer similar to the SAXS measurement (10 mM Tris pH 7.4, 300 mM NaCl, 1 mM &#x003b2;-mercapto ethanol). All other titrations were carried out in 20 mM sodium phosphate pH 7.1, 300 mM NaCl, 2 mM EGTA and 1 mM &#x003b2;-mercapto ethanol. ITC was performed at 20&#x000b0;C with a VP-ITC microcalorimeter from MicroCal Incorporated. For the AKT_PH &#x02013;TCL1A titration, TCL1A was placed in the 1.4 mL sample cell at a concentration of 40 &#x000b5;M, and AKT_PH (490 &#x000b5;M) was injected using 10&#x02013;15 &#x000b5;l injections every 300 s. For the IkB&#x003b1;&#x02013;TCL1A titration, I&#x003ba;B_ank<sup>7CS</sup> (45 &#x000b5;M) was kept in the sample cell, and TCL1A (470 &#x000b5;M) was injected. Competition experiments were performed by placing equimolar amounts of TCL1A and I&#x003ba;B_ank<sup>7CS</sup> in the sample cell, and injecting AKT_PH. For all protein-protein titrations, control experiments were performed where the corresponding protein was injected in buffer alone. The resulting heats were subtracted from the protein-protein titrations prior to analysis. Data were fitted with Microcal Origin software.</p></sec><sec id="s4h"><title>SAXS analysis</title><p>Data used for this SAXS analysis were collected at beamline X33, at DESY, EMBL, Hamburg, at 10&#x000b0;C, &#x003bb;&#x0200a;&#x0003d;&#x0200a;1.5 &#x000c5;. Additional preliminary data were collected at the ESRF beamline ID14-3. For SAXS analysis of the TCL1A&#x02236;I&#x003ba;B_ank<sup>7CS</sup> complex, the partners were pre-purified individually, then mixed in a 1&#x02236;1 ratio, and applied to a S200 size-exclusion column (Pharmacia). Only eluted fractions corresponding to the 2&#x000d7;2 TCL1A&#x02236;I&#x003ba;B_ank<sup>7CS</sup> dimer were used for SAXS. Samples were kept in 10 mM Tris, pH 7.4, 300 mM NaCl, 1 mM &#x003b2;-mercapto ethanol and supplemented with 5 mM DTT prior to exposure. Data collected on purified TCL1A&#x02236;I&#x003ba;B_ank<sup>7CS</sup> at 1 and 7 mg/ml were merged to combine the aggregate-free low resolution-part of the 1 mg/ml scattering curve with the reduced noise at high resolution of the 7 mg/ml data. Data analysis, <italic>ab initio</italic> shape calculations, and rigid body docking were performed using programs by S. Svergun and colleagues (PRIMUS, GNOM, DAMMIN, CRYSOL, DAMAVER and SASREF <xref ref-type="bibr" rid="pone.0006567-Koch1">&#x0005b;13&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0006567-Svergun2">&#x0005b;16&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0006567-Konarev1">&#x0005b;26&#x0005d;</xref>&#x02013;<xref ref-type="bibr" rid="pone.0006567-Svergun3">&#x0005b;28&#x0005d;</xref>). For GASBOR different q ranges (0.020&#x02013;0.45 &#x000c5;<sup>&#x02212;1</sup> or 0.028&#x02013;0.40 &#x000c5;<sup>&#x02212;1</sup>) gave very similar results. For SASREF rigid body docking, P2 symmetry was used. The TCL1A dimer was obtained from the PDB entry 1JSG <xref ref-type="bibr" rid="pone.0006567-Hoh1">&#x0005b;14&#x0005d;</xref>), and this dimeric arrangement was kept fixed during rigid body docking. I&#x003ba;B_ank was obtained from PDB entry 1NFI <xref ref-type="bibr" rid="pone.0006567-Jacobs1">&#x0005b;12&#x0005d;</xref>. The regions not included into the crystallographic models (7 N-terminal residues for TCL1A, and 20 C-terminal residues for I&#x003ba;B_ank) were modelled as extended unstructured regions and included as rigid fragments in SASREF modelling. For this, the 20 C-terminal residues of I&#x003ba;B_ank were divided into two rigid 10-residue fragments. The fragments forming one polypeptide chain were connected using the constraint that connecting residues lie within 4.0 &#x000c5; of each other. SASREF models for different q ranges (0.020&#x02013;0.40 &#x000c5;<sup>&#x02212;1</sup> or 0.028&#x02013;0.40 &#x000c5;<sup>&#x02212;1</sup>) were very similar.</p></sec></sec><sec sec-type="supplementary-material" id="s5"><title>Supporting Information</title><supplementary-material content-type="local-data" id="pone.0006567.s001"><label>Figure S1</label><caption><p>Binding assays. (a) Glutathione-sepharose beads containing GST_TCL1A alone, or GST_TCL1A and indicated ligands, were washed and analysed by SDS PAGE gels as described in Supplementary Methods. Notch ank has the same molecular weight (26 kDa) as I&#x003ba;B_ank. (b) Native gel shift assays, stained with coomassie blue, or (c) revealed by Western blotting, using a mouse anti-I&#x003ba;B&#x003b1; antibody.</p><p>(0.30 MB TIF)</p></caption><media xlink:href="pone.0006567.s001.tif" mimetype="image" mime-subtype="tiff"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0006567.s002"><label>Figure S2</label><caption><p>Supporting ITC data. All experiments were performed at 20&#x000b0;C. Upper panels show the binding isotherms (black) and their control experiments (blue) where the syringe content was injected into the cell containing only buffer. Lower panels show integrated heats, after subtraction of heats from control experiments (dots). The black lines represent least-square fits of data. (a) ITC binding isotherm obtained when AKT_PH was injected into the TCL1A-containing cell. (b) ITC binding isotherm for AKT_PH injected into the cell containing the TCL1A:I&#x003ba;B_ank7CS complex.</p><p>(0.19 MB DOC)</p></caption><media xlink:href="pone.0006567.s002.doc" mimetype="application" mime-subtype="msword"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0006567.s003"><label>Figure S3</label><caption><p>SAXS Distance distribution &#x0005b;P(r)&#x0005d; and SASREF results. (a) P(r) distance distribution, and (b) fit of best GASBOR model to data (q&#x0200a;&#x0003d;&#x0200a;0.02&#x02013;0.45 &#x000c5;<sup>&#x02212;1</sup>).</p><p>(0.06 MB DOC)</p></caption><media xlink:href="pone.0006567.s003.doc" mimetype="application" mime-subtype="msword"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></sec></body><back><ack><p>We thank G. Pierron for her contribution in two-hybrid screening, D. Auguin for comments, J.-B. Rouget for the Notch ankyrin protein, G. Ghosh and M. Benkirane for I&#x003ba;B and RELA expression plasmids, respectively. We are grateful to J.-B. Charbonnier for giving us access to protein expression and purification facilities for preparing the revised manuscript. We thank S. Miron for access to the ITC microcalorimeter. We thank J.-L. Pons and E. Richard for their assistance with computational analyses on the computer cluster of the Centre de Biochimie Structurale. We thank D. Svergun and his colleagues at the X33 beamline at EMBL/DESY, Hamburg, as well as P. Pernot and A. Round from the ESRF beamline ID14-3 for assistance with SAXS analysis.</p></ack><ref-list><title>References</title><ref id="pone.0006567-Teitell1"><label>1</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Teitell</surname><given-names>MA</given-names></name></person-group><year>2005</year><article-title>The TCL1 family of oncoproteins: co-activators of transformation.</article-title><source>Nat Rev Cancer</source><volume>5</volume><fpage>640</fpage><lpage>648</lpage><pub-id pub-id-type="pmid">16056259</pub-id></mixed-citation></ref><ref id="pone.0006567-Noguchi1"><label>2</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Noguchi</surname><given-names>M</given-names></name><name><surname>Ropars</surname><given-names>V</given-names></name><name><surname>Roumestand</surname><given-names>C</given-names></name><name><surname>Suizu</surname><given-names>F</given-names></name></person-group><year>2007</year><article-title>Proto-oncogene TCL1: more than just a coactivator for Akt.</article-title><source>Faseb J</source><volume>21</volume><fpage>2273</fpage><lpage>2284</lpage><pub-id pub-id-type="pmid">17360849</pub-id></mixed-citation></ref><ref id="pone.0006567-Laine1"><label>3</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Laine</surname><given-names>J</given-names></name><name><surname>Kunstle</surname><given-names>G</given-names></name><name><surname>Obata</surname><given-names>T</given-names></name><name><surname>Sha</surname><given-names>M</given-names></name><name><surname>Noguchi</surname><given-names>M</given-names></name></person-group><year>2000</year><article-title>The protooncogene TCL1 is an Akt kinase coactivator.</article-title><source>Mol Cell</source><volume>6</volume><fpage>395</fpage><lpage>407</lpage><pub-id pub-id-type="pmid">10983986</pub-id></mixed-citation></ref><ref id="pone.0006567-Pekarsky1"><label>4</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pekarsky</surname><given-names>Y</given-names></name><name><surname>Koval</surname><given-names>A</given-names></name><name><surname>Hallas</surname><given-names>C</given-names></name><name><surname>Bichi</surname><given-names>R</given-names></name><name><surname>Tresini</surname><given-names>M</given-names></name><etal/></person-group><year>2000</year><article-title>Tcl1 enhances Akt kinase activity and mediates its nuclear translocation.</article-title><source>Proc Natl Acad Sci U S A</source><volume>97</volume><fpage>3028</fpage><lpage>3033</lpage><pub-id pub-id-type="pmid">10716693</pub-id></mixed-citation></ref><ref id="pone.0006567-Auguin1"><label>5</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Auguin</surname><given-names>D</given-names></name><name><surname>Barthe</surname><given-names>P</given-names></name><name><surname>Royer</surname><given-names>C</given-names></name><name><surname>Stern</surname><given-names>MH</given-names></name><name><surname>Noguchi</surname><given-names>M</given-names></name><etal/></person-group><year>2004</year><article-title>Structural basis for the co-activation of protein kinase B by T-cell leukemia-1 (TCL1) family proto-oncoproteins.</article-title><source>J Biol Chem</source><volume>279</volume><fpage>35890</fpage><lpage>35902</lpage><pub-id pub-id-type="pmid">15169787</pub-id></mixed-citation></ref><ref id="pone.0006567-Manning1"><label>6</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Manning</surname><given-names>BD</given-names></name><name><surname>Cantley</surname><given-names>LC</given-names></name></person-group><year>2007</year><article-title>AKT/PKB signaling: navigating downstream.</article-title><source>Cell</source><volume>129</volume><fpage>1261</fpage><lpage>1274</lpage><pub-id pub-id-type="pmid">17604717</pub-id></mixed-citation></ref><ref id="pone.0006567-Ozes1"><label>7</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ozes</surname><given-names>ON</given-names></name><name><surname>Mayo</surname><given-names>LD</given-names></name><name><surname>Gustin</surname><given-names>JA</given-names></name><name><surname>Pfeffer</surname><given-names>SR</given-names></name><name><surname>Pfeffer</surname><given-names>LM</given-names></name><etal/></person-group><year>1999</year><article-title>NF-kappaB activation by tumour necrosis factor requires the Akt serine-threonine kinase.</article-title><source>Nature</source><volume>401</volume><fpage>82</fpage><lpage>85</lpage><pub-id pub-id-type="pmid">10485710</pub-id></mixed-citation></ref><ref id="pone.0006567-Hayden1"><label>8</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hayden</surname><given-names>MS</given-names></name><name><surname>Ghosh</surname><given-names>S</given-names></name></person-group><year>2008</year><article-title>Shared principles in NF-kappaB signaling.</article-title><source>Cell</source><volume>132</volume><fpage>344</fpage><lpage>362</lpage><pub-id pub-id-type="pmid">18267068</pub-id></mixed-citation></ref><ref id="pone.0006567-Pekarsky2"><label>9</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pekarsky</surname><given-names>Y</given-names></name><name><surname>Zanesi</surname><given-names>N</given-names></name><name><surname>Aqeilan</surname><given-names>RI</given-names></name><name><surname>Croce</surname><given-names>CM</given-names></name></person-group><year>2007</year><article-title>Animal models for chronic lymphocytic leukemia.</article-title><source>J Cell Biochem</source><volume>100</volume><fpage>1109</fpage><lpage>1118</lpage><pub-id pub-id-type="pmid">17131382</pub-id></mixed-citation></ref><ref id="pone.0006567-Pekarsky3"><label>10</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pekarsky</surname><given-names>Y</given-names></name><name><surname>Palamarchuk</surname><given-names>A</given-names></name><name><surname>Maximov</surname><given-names>V</given-names></name><name><surname>Efanov</surname><given-names>A</given-names></name><name><surname>Nazaryan</surname><given-names>N</given-names></name><etal/></person-group><year>2008</year><article-title>Tcl1 functions as a transcriptional regulator and is directly involved in the pathogenesis of CLL.</article-title><source>Proc Natl Acad Sci U S A</source><volume>105</volume><fpage>19643</fpage><lpage>19648</lpage><pub-id pub-id-type="pmid">19064921</pub-id></mixed-citation></ref><ref id="pone.0006567-Huxford1"><label>11</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huxford</surname><given-names>T</given-names></name><name><surname>Huang</surname><given-names>DB</given-names></name><name><surname>Malek</surname><given-names>S</given-names></name><name><surname>Ghosh</surname><given-names>G</given-names></name></person-group><year>1998</year><article-title>The crystal structure of the IkappaBalpha/NF-kappaB complex reveals mechanisms of NF-kappaB inactivation.</article-title><source>Cell</source><volume>95</volume><fpage>759</fpage><lpage>770</lpage><pub-id pub-id-type="pmid">9865694</pub-id></mixed-citation></ref><ref id="pone.0006567-Jacobs1"><label>12</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jacobs</surname><given-names>MD</given-names></name><name><surname>Harrison</surname><given-names>SC</given-names></name></person-group><year>1998</year><article-title>Structure of an IkappaBalpha/NF-kappaB complex.</article-title><source>Cell</source><volume>95</volume><fpage>749</fpage><lpage>758</lpage><pub-id pub-id-type="pmid">9865693</pub-id></mixed-citation></ref><ref id="pone.0006567-Koch1"><label>13</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Koch</surname><given-names>MH</given-names></name><name><surname>Vachette</surname><given-names>P</given-names></name><name><surname>Svergun</surname><given-names>DI</given-names></name></person-group><year>2003</year><article-title>Small-angle scattering: a view on the properties, structures and structural changes of biological macromolecules in solution.</article-title><source>Q Rev Biophys</source><volume>36</volume><fpage>147</fpage><lpage>227</lpage><pub-id pub-id-type="pmid">14686102</pub-id></mixed-citation></ref><ref id="pone.0006567-Hoh1"><label>14</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hoh</surname><given-names>F</given-names></name><name><surname>Yang</surname><given-names>YS</given-names></name><name><surname>Guignard</surname><given-names>L</given-names></name><name><surname>Padilla</surname><given-names>A</given-names></name><name><surname>Stern</surname><given-names>MH</given-names></name><etal/></person-group><year>1998</year><article-title>Crystal structure of p14<italic><sup>TCL1</sup></italic>, an oncogene product involved in T-cell prolymphocytic leukemia, reveals a novel beta-barrel topology.</article-title><source>Structure</source><volume>6</volume><fpage>147</fpage><lpage>155</lpage><pub-id pub-id-type="pmid">9519406</pub-id></mixed-citation></ref><ref id="pone.0006567-Svergun1"><label>15</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Svergun</surname><given-names>DI</given-names></name><name><surname>Petoukhov</surname><given-names>MV</given-names></name><name><surname>Koch</surname><given-names>MH</given-names></name></person-group><year>2001</year><article-title>Determination of domain structure of proteins from X-ray solution scattering.</article-title><source>Biophys J</source><volume>80</volume><fpage>2946</fpage><lpage>2953</lpage><pub-id pub-id-type="pmid">11371467</pub-id></mixed-citation></ref><ref id="pone.0006567-Svergun2"><label>16</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Svergun</surname><given-names>DI</given-names></name><name><surname>Barberato</surname><given-names>C</given-names></name><name><surname>Koch</surname><given-names>MHJ</given-names></name></person-group><year>1995</year><article-title>CRYSOL - a Program to Evaluate X-ray Solution Scattering of Biological Macromolecules from Atomic Coordinates.</article-title><source>J Appl Cryst</source><volume>28</volume><fpage>768</fpage><lpage>773</lpage></mixed-citation></ref><ref id="pone.0006567-Volkov1"><label>17</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Volkov</surname><given-names>VV</given-names></name><name><surname>Svergun</surname><given-names>DI</given-names></name></person-group><year>2003</year><article-title>Uniqueness of <italic>ab initio</italic> shape determination in small-angle scattering.</article-title><source>J Appl Cryst</source><fpage>860</fpage><lpage>864</lpage></mixed-citation></ref><ref id="pone.0006567-Despouy1"><label>18</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Despouy</surname><given-names>G</given-names></name><name><surname>Joiner</surname><given-names>M</given-names></name><name><surname>Le Toriellec</surname><given-names>E</given-names></name><name><surname>Weil</surname><given-names>R</given-names></name><name><surname>Stern</surname><given-names>MH</given-names></name></person-group><year>2007</year><article-title>The TCL1 oncoprotein inhibits activation-induced cell death by impairing PKCtheta and ERK pathways.</article-title><source>Blood</source><volume>110</volume><fpage>4406</fpage><lpage>4416</lpage><pub-id pub-id-type="pmid">17846228</pub-id></mixed-citation></ref><ref id="pone.0006567-Bergqvist1"><label>19</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bergqvist</surname><given-names>S</given-names></name><name><surname>Croy</surname><given-names>CH</given-names></name><name><surname>Kjaergaard</surname><given-names>M</given-names></name><name><surname>Huxford</surname><given-names>T</given-names></name><name><surname>Ghosh</surname><given-names>G</given-names></name><etal/></person-group><year>2006</year><article-title>Thermodynamics reveal that helix four in the NLS of NF-kappaB p65 anchors IkappaBalpha, forming a very stable complex.</article-title><source>J Mol Biol</source><volume>360</volume><fpage>421</fpage><lpage>434</lpage><pub-id pub-id-type="pmid">16756995</pub-id></mixed-citation></ref><ref id="pone.0006567-Tergaonkar1"><label>20</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tergaonkar</surname><given-names>V</given-names></name><name><surname>Correa</surname><given-names>RG</given-names></name><name><surname>Ikawa</surname><given-names>M</given-names></name><name><surname>Verma</surname><given-names>IM</given-names></name></person-group><year>2005</year><article-title>Distinct roles of IkappaB proteins in regulating constitutive NF-kappaB activity.</article-title><source>Nat Cell Biol</source><volume>7</volume><fpage>921</fpage><lpage>923</lpage><pub-id pub-id-type="pmid">16136188</pub-id></mixed-citation></ref><ref id="pone.0006567-Bouhamdan1"><label>21</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bouhamdan</surname><given-names>M</given-names></name><name><surname>Benichou</surname><given-names>S</given-names></name><name><surname>Rey</surname><given-names>F</given-names></name><name><surname>Navarro</surname><given-names>JM</given-names></name><name><surname>Agostini</surname><given-names>I</given-names></name><etal/></person-group><year>1996</year><article-title>Human immunodeficiency virus type 1 Vpr protein binds to the uracil DNA glycosylase DNA repair enzyme.</article-title><source>J Virol</source><volume>70</volume><fpage>697</fpage><lpage>704</lpage><pub-id pub-id-type="pmid">8551605</pub-id></mixed-citation></ref><ref id="pone.0006567-Despouy2"><label>22</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Despouy</surname><given-names>G</given-names></name><name><surname>Bastie</surname><given-names>JN</given-names></name><name><surname>Deshaies</surname><given-names>S</given-names></name><name><surname>Balitrand</surname><given-names>N</given-names></name><name><surname>Mazharian</surname><given-names>A</given-names></name><etal/></person-group><year>2003</year><article-title>Cyclin D3 is a cofactor of retinoic acid receptors, modulating their activity in the presence of cellular retinoic acid-binding protein II.</article-title><source>J Biol Chem</source><volume>278</volume><fpage>6355</fpage><lpage>6362</lpage><pub-id pub-id-type="pmid">12482873</pub-id></mixed-citation></ref><ref id="pone.0006567-Huxford2"><label>23</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huxford</surname><given-names>T</given-names></name><name><surname>Malek</surname><given-names>S</given-names></name><name><surname>Ghosh</surname><given-names>G</given-names></name></person-group><year>2000</year><article-title>Preparation and crystallization of dynamic NF-kappa B.Ikappa B complexes.</article-title><source>J Biol Chem</source><volume>275</volume><fpage>32800</fpage><lpage>32806</lpage><pub-id pub-id-type="pmid">10906335</pub-id></mixed-citation></ref><ref id="pone.0006567-Kiernan1"><label>24</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kiernan</surname><given-names>R</given-names></name><name><surname>Bres</surname><given-names>V</given-names></name><name><surname>Ng</surname><given-names>RW</given-names></name><name><surname>Coudart</surname><given-names>MP</given-names></name><name><surname>El Messaoudi</surname><given-names>S</given-names></name><etal/></person-group><year>2003</year><article-title>Post-activation turn-off of NF-kappa B-dependent transcription is regulated by acetylation of p65.</article-title><source>J Biol Chem</source><volume>278</volume><fpage>2758</fpage><lpage>2766</lpage><pub-id pub-id-type="pmid">12419806</pub-id></mixed-citation></ref><ref id="pone.0006567-Auguin2"><label>25</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Auguin</surname><given-names>D</given-names></name><name><surname>Barthe</surname><given-names>P</given-names></name><name><surname>Auge-Senegas</surname><given-names>MT</given-names></name><name><surname>Stern</surname><given-names>MH</given-names></name><name><surname>Noguchi</surname><given-names>M</given-names></name><etal/></person-group><year>2004</year><article-title>Solution structure and backbone dynamics of the pleckstrin homology domain of the human protein kinase B (PKB/Akt). Interaction with inositol phosphates.</article-title><source>J Biomol NMR</source><volume>28</volume><fpage>137</fpage><lpage>155</lpage><pub-id pub-id-type="pmid">14755158</pub-id></mixed-citation></ref><ref id="pone.0006567-Konarev1"><label>26</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Konarev</surname><given-names>PV</given-names></name><name><surname>Vladimir</surname><given-names>VV</given-names></name><name><surname>Sokolova</surname><given-names>AV</given-names></name><name><surname>Koch</surname><given-names>MJ</given-names></name><name><surname>Svergun</surname><given-names>DI</given-names></name></person-group><year>2003</year><article-title>PRIMUS: a Window PC-based system for small-angle scattering data.</article-title><source>J Appl Cryst</source><volume>36</volume><fpage>1277</fpage><lpage>1282</lpage></mixed-citation></ref><ref id="pone.0006567-Petoukhov1"><label>27</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Petoukhov</surname><given-names>MV</given-names></name><name><surname>Svergun</surname><given-names>DI</given-names></name></person-group><year>2005</year><article-title>Global rigid body modeling of macromolecular complexes against small-angle scattering data.</article-title><source>Biophys J</source><volume>89</volume><fpage>1237</fpage><lpage>1250</lpage><pub-id pub-id-type="pmid">15923225</pub-id></mixed-citation></ref><ref id="pone.0006567-Svergun3"><label>28</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Svergun</surname><given-names>DI</given-names></name></person-group><year>1992</year><article-title>Determination of the Regularization Parameter in Indirect-Transform Methods Using Perceptual Criteria.</article-title><source>J Appl Cryst</source><volume>25</volume><fpage>495</fpage><lpage>503</lpage></mixed-citation></ref></ref-list><fn-group><fn fn-type="conflict"><p><bold>Competing Interests: </bold>The authors have declared that no competing interests exist.</p></fn><fn fn-type="financial-disclosure"><p><bold>Funding: </bold>This study was supported by the European Community-Research Infrastructure Action under the FP6 (RII3/CT/2004/5060008) for access to EMBL/DESY, Hamburg, and by the Association pour la Recherche contre le Cancer (ARC). V.R. received funding from ARC and the Ligue Nationale contre le Cancer. G.D. received funding from the Fondation de France and the Canceropole-Ile-de-France. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</p></fn></fn-group></back></article>